Fig. 1 · Structure

Documents & Downloads

Paliperidone

Cat. No. A10691 CAS 144598-75-4

Dopamine Receptor antagonist

Paliperidone(Invega) is an atypical antipsychotic.

In Stock

Publications for Paliperidone

1 publication citing this product

  1. Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Paliperidone showed acute inverse agonist activity at human dopamine D2 receptors in HEK-D2 cells: it increased forskolin-stimulated cAMP accumulation and reduced basal ERK activity. Both responses were greater than those of risperidone under the tested conditions. These findings describe specific cellular assays rather than a uniform response across pathways or exposure durations. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Dopamine receptor

Cellular Effect

Cell Line Activity Value Description Reference
CHO IC50 193.9 μM Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits [PMID: 23812503]

In Vitro Studies

At 100 nM, paliperidone reduced basal IP accumulation in human 5-HT2A receptor-expressing cells but did not significantly inhibit basal arachidonic acid release. It also weakly stimulated β-arrestin recruitment. This pathway-dependent profile limits a blanket description of all 5-HT2A responses as blockade. [1]

Acute dopamine D2 receptor signalling

Cell-based study · HEK-293 cells stably expressing human dopamine D2 receptors (HEK-D2). [1]

Paliperidone increased forskolin-stimulated cAMP accumulation and reduced basal ERK activity, consistent with inverse agonism in these acute assays. Responses exceeded those of risperidone in the reported comparisons.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Forskolin-stimulated cAMP accumulation (six independent experiments; bars mean ± SEM)Reported direction and statistical comparison Increased versus vehicle; paliperidone greater than risperidone, P < 0.05.[1]
Basal ERK activity (five independent experiments; bars mean ± SEM)Approximate reduction reported in text Approximately 35%; paliperidone greater inverse agonist efficacy than risperidone, P < 0.05.[1]

Literature-Reported Treatment Conditions

Treatment concentration
Paliperidone 200 nM; risperidone 300 nM and butaclamol 1 μM as separate comparators.
Exposure duration
cAMP: 15 min ligand pretreatment followed by an additional 15 min with forskolin; ERK: 5 min ligand treatment.
Method
cAMP measured by RIA with forskolin 1 μM; pERK measured using the SureFire assay.
Co-treatment
Forskolin 1 μM stimulates adenylyl cyclase in the cAMP assay; comparator ligands were tested separately.
Reported limits
Vehicle composition is not specified in the acquired Methods. Exact cAMP effect magnitude is not adopted because text and plotted normalization differ.
Methods and source locations

Compound reported in the paper: Paliperidone; Compound label in the paper: Paliperidone (9-hydroxyrisperidone)

Results concern the named research compound in receptor-expressing cells; no salt conversion, ester equivalence or lot validation is inferred.

Figure 6A–B; Results/Dopamine D2 receptor signalling; Methods/Cell culture, cAMP accumulation and ERK activity

Forskolin-stimulated cAMP accumulation (six independent experiments; bars mean ± SEM): RIA; vehicle and separate butaclamol/risperidone comparators; quinpirole positive control inhibited cAMP as reported in caption. — Figure 6A image/caption; Methods/cAMP accumulation; Results/Dopamine D2 receptor signalling

Basal ERK activity (five independent experiments; bars mean ± SEM): SureFire pERK assay; acute 5 min exposure; Figure 6B comparison marker checked visually. No exact value or SEM estimated from bars. — Figure 6B image/caption; Results/Dopamine D2 receptor signalling; Methods/ERK activity

Acute serotonin 5-HT2A receptor signalling

Cell-based study · Human 5-HT2A receptor-expressing HEK-2A cells (IP accumulation), CHO-FA4 cells (AA release), and tagged-receptor U2OS cells (β-arrestin recruitment). [1]

Paliperidone reduced basal IP accumulation, did not significantly inhibit basal AA release, and weakly increased β-arrestin recruitment. The profile therefore depends on the measured signalling pathway.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Basal IP accumulation in HEK-2A cellsReduction from basal 39 ± 5% (mean ± SEM; 3–6 experiments across Figure 4 panel).[1]
Basal AA release in CHO-FA4 cellsReported null response No significant inhibition by paliperidone.[1]
β-arrestin recruitment in tagged-receptor U2OS cellsIncrease above basal 165 ± 25% (mean ± SEM; 3–6 experiments across Figure 4 panel).[1]

Literature-Reported Treatment Conditions

Treatment concentration
Paliperidone 100 nM; risperidone 30 nM and ketanserin 1 μM as separate comparators.
Exposure duration
IP accumulation and AA release: 30 min; β-arrestin recruitment: 90 min.
Method
IP accumulation, AA release and PathHunter β-arrestin assays in the respective receptor-expressing cell lines.
Co-treatment
No co-treatment for basal ligand-response measurements; serotonin 10 μM was a separate β-arrestin agonist control.
Reported limits
Vehicle composition is not specified. Figure 4 reports 3–6 experiments across its panel without assigning an exact n to each adopted endpoint.
Methods and source locations

Compound reported in the paper: Paliperidone; Compound label in the paper: Paliperidone (9-hydroxyrisperidone)

Results concern the named research compound in receptor-expressing cells; no salt conversion, ester equivalence or lot validation is inferred.

Figure 4; Results/5-HT2A receptor signalling; Methods/Cell culture, IP accumulation, AA release and β-arrestin recruitment

Basal IP accumulation in HEK-2A cells: 30 min treatment; IP accumulation; ketanserin and risperidone reference conditions. — Results/5-HT2A receptor signalling, first paragraph; Figure 4 image/caption

Basal AA release in CHO-FA4 cells: 30 min treatment; AA-release assay; risperidone significantly reduced AA release in the same comparison panel. — Results/5-HT2A receptor signalling, first paragraph; Figure 4 image/caption

β-arrestin recruitment in tagged-receptor U2OS cells: 90 min treatment; PathHunter assay. Serotonin 10 μM produced 660 ± 50% above basal (mean ± SEM, n = 6), supporting the paper’s weak-agonist characterization. — Results/5-HT2A receptor signalling, first paragraph; Figure 4 image/caption; Methods/β-arrestin recruitment

In Vivo Studies

In five male rhesus monkeys, continuous intragastric paliperidone produced a significant dose-dependent increase in basal-ganglia D2 receptor occupancy. Cortical occupancy estimates were more variable, and their dose trend was not statistically significant (p = 0.057). This PET experiment measured receptor engagement in healthy animals; it did not test symptom improvement. [2]

Dopamine D2 receptor occupancy during repeated paliperidone infusion

Animal study · Five male rhesus monkeys (Macaca mulatta), 4.2–6.3 years; within-subject [18F]fallypride PET study. [2]

Dose-dependent D2 occupancy was significant in basal ganglia. Cortical estimates were more variable, and the paliperidone cortical dose trend was not significant. Repeated treatment did not significantly change off-drug binding potential after washout.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Dose effect on mean D2 occupancy across caudate, putamen and ventral striatumOne-way repeated-measures ANOVA F3,12 = 23.977; p < 0.001[2]
Dose effect on mean D2 occupancy across four cortical regionsOne-way repeated-measures ANOVA F3,12 = 3.309; p = 0.057[2]
Off-drug D2 binding potential over repeated risperidone/paliperidone treatment and washout cyclesRepeated-measures ANOVAs, corrected for multiple comparisons p > 0.05 for all regions of interest[2]

Conditions shared by the study groups

Route
Continuous intragastric infusion through a catheter supplied by an osmotic pump.
Frequency
Continuous
Treatment course
Two-week treatment periods, on-drug PET after 12 days; off-drug scans after 26 days of washout.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Within-animal paliperidone dose series
0.05, 0.1, 0.2 and 0.6 mg/kg/day
Within-subject comparison with the average of eight off-drug scans; saline infusion during washout. Risperidone was a separate comparator, not a combination treatment.Basal-ganglia occupancy increased with dose (F3,12 = 23.977; p < 0.001). The cortical dose trend did not reach significance (F3,12 = 3.309; p = 0.057).[2]
Within-animal paliperidone dose series
Model: Five male rhesus monkeys, age 4.2–6.3 years; the same animals received all four paliperidone doses and separate risperidone treatment periods.
Reported limits: Study-drug infusion vehicle is not specified; washout saline is not assumed to be that vehicle. Healthy animals do not establish schizophrenia symptom benefit.
Methods and source locations

Compound reported in the paper: Paliperidone; Compound label in the paper: Paliperidone (9-hydroxyrisperidone)

Parent paliperidone in a monkey intragastric infusion model; no palmitate depot, marketed tablet or Adooq lot equivalence is inferred.

Methods/Chronic Treatment Study, PET Image Analysis and Statistical Analyses; Results/Baseline Regional D2R Binding Potential and D2R Occupancy; Figures 1, 6B and 7B

Dose effect on mean D2 occupancy across caudate, putamen and ventral striatum: Five animals at four paliperidone doses; occupancy relative to averaged off-drug scans. Figure 6B visually checked; no exact percentages digitized. — Results/D2R Occupancy of Risperidone and Paliperidone, first paragraph; Figure 6B

Dose effect on mean D2 occupancy across four cortical regions: Four cortical regions averaged for each animal; greater variability than basal ganglia. Figure 7B visually checked. — Results/D2R Occupancy of Risperidone and Paliperidone, paragraph preceding Figure 7; Figure 7B

Off-drug D2 binding potential over repeated risperidone/paliperidone treatment and washout cycles: Eight off-drug scans per animal; this null result concerns the shared treatment sequence, not an isolated paliperidone-only washout arm. — Results/Baseline Regional D2R Binding Potential, first paragraph; Methods/PET Image Analysis

Within-animal paliperidone dose series · Methods/Chronic Treatment Study and PET Image Analysis; Figure 1; Results/D2R Occupancy; Figures 6B and 7B

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 144598-75-4
Applications Dopamine Receptor antagonist
Formula C23H27FN4O3
Molecular Weight 426.48
Synonyms Invega; INVEGA Sustenna; 9-hydroxyrisperidone
SMILES
CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 4 mg/mL (9.37 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Clarke WP, Chavera TA, Silva M, et al. Signalling profile differences: paliperidone versus risperidone British journal of pharmacology (2013). PMID: 23826915 DOI: 10.1111/bph.12295 Source material
  2. [2] Muly EC, Votaw JR, Ritchie J, et al. Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone The Journal of pharmacology and experimental therapeutics (2012). PMID: 22214649 DOI: 10.1124/jpet.111.189076 Source material

Publications

1 publication citing this product

  1. Reiko Watanabe, .et al. , J Med Chem, 2021, Mar 11;64(5):2725-2738 PMID: 33619967

Added to your cart

View Cart Checkout
Loading...